ArticleTherapeutic advances in gastroenterology2012
Overutilization of proton-pump inhibitors: what the clinician needs to know.
Article in Therapeutic advances in gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 9 syntheses or guidelines pooled it, 319 citations in OpenAlex.
- The impact of proton pump inhibitor exposure on pneumonia: an updated meta-analysis based on randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Meta-analysis of the effects of proton pump inhibitors on the human gut microbiota.BMC microbiology · 2023Pooled it
- Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies.Bioscience reports · 2020Pooled it
- Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis.World journal of gastroenterology · 2019Pooled it
- Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.Digestive diseases and sciences · 2017Pooled it
- Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.Canadian family physician Medecin de famille canadien · 2017Guideline
- Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults.Drugs & aging · 2017Pooled it
- Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.Journal of managed care & specialty pharmacy · 2016Pooled it
- Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk.Pain practice : the official journal of World Institute of Pain · 2014Pooled it
- Deprescription of proton pump inhibitors in the primary care setting in the Canary Islands. A randomized massive educational intervention.BMC primary care · 2026Trial
- Direct-to-consumer strategies to promote deprescribing in primary care: a pilot study.BMC primary care · 2022Trial
- Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.Alzheimer's research & therapy · 2015Trial
- PPI Misuse in Bangladesh: Confronting a Silent Epidemic Through Deprescribing and Regulatory Reform-A Policy Perspective.Health science reports · 2026Article
- Article
- Article
- Visibility Evaluation of Fundic Gland Polyp Associated With Proton Pump Inhibitor in Texture and Color Enhancement Imaging.DEN open · 2026Article
- Acid-Suppressive Therapy Choice and Risk of Treatment Escalation in Inflammatory Bowel Disease: A Real-World Comparative Retrospective Study to Inform Personalized Treatment.Journal of personalized medicine · 2026Article
- Vietnam Association of Gastroenterology (VNAGE) guideline on the management of gastroesophageal reflux disease.Frontiers in medicine · 2026Review
- Impact of an IV proton pump inhibitor restriction policy on prescribing patterns and estimated drug cost.Frontiers in pharmacology · 2026Article
- Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases.Medicine · 2025Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton-pump inhibitors (PPIs) remain the leading evidence-based therapy for upper gastrointestinal disorders, including gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease. The effectiveness of PPIs has led to overutilization in multiple treatment arenas, exposing patients to an increasing number of potential risks. The overutilization of PPIs in ambulatory care settings is often a result of failure to re-evaluate the need for continuation of therapy, or insufficient use of on-demand and step-down therapy. PPI overutilization in the inpatient setting is often a result of inappropriate stress ulcer prophylaxis (SUP) in nonintensive care unit patients, and failure to discontinue SUP prior to hospital discharge. Potential consequences of prolonged PPI therapy include hypergastrinemia, enterochromaffin-like cell hyperplasia, and parietal cell hypertrophy, leading to rebound acid hypersecretion. PPIs have been linked via retrospective studies to increased risk of enteric infections including Clostridium difficile-associated diarrhea, community-acquired pneumonia, bone fracture, nutritional deficiencies, and interference with metabolism of antiplatelet agents. Reducing inappropriate prescribing of PPIs in the inpatient and outpatient settings can minimize potential for adverse events, and foster controllable cost expenditure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.